1
|
Osman AM, Mukherjee S, Altree TJ, Delbeck M, Gehring D, Hahn M, Lang T, Xing C, Muller T, Weimann G, Eckert DJ. Topical Potassium Channel Blockage Improves Pharyngeal Collapsibility: A Translational, Placebo-Controlled Trial. Chest 2022; 163:953-965. [PMID: 36435266 DOI: 10.1016/j.chest.2022.11.024] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2022] [Revised: 10/06/2022] [Accepted: 11/02/2022] [Indexed: 11/27/2022] Open
Abstract
BACKGROUND Potassium channel inhibition has been identified in animal models as a potential target to increase pharyngeal dilator muscle activity and to treat OSA. However, these findings have not yet been translated to humans. RESEARCH QUESTION Does a novel, potent, TWIK-related acid-sensitive K+ (TASK) 1/3 channel antagonist, BAY2586116, improve pharyngeal collapsibility in pigs and humans, and secondarily, what is the optimal dose and method of topical application? STUDY DESIGN AND METHODS In the preclinical study, pharyngeal muscle activity and upper-airway collapsibility via transient negative pressure application was quantified in 13 anesthetized pigs during administration of placebo, 0.3 μg, 3 μg, and 30 μg nasal drops of BAY2586116. In the clinical study, 12 people with OSA instrumented with polysomnography equipment, an epiglottic pressure catheter, pneumotachograph, and nasal mask to monitor sleep and breathing performed up to four detailed upper airway sleep physiology studies. Participants received BAY2586116 or placebo nasal spray (160 μg) before sleep via a double-masked, randomized, crossover design. Most participants also returned for three additional overnight visits: (1) nasal drops (160 μg), (2) half-dose nasal spray (80 μg), and (3) direct endoscopic application (160 μg). The upper-airway critical closing pressure during sleep was quantified at each visit. RESULTS Consistent and sustained improvements in pharyngeal collapsibility to negative pressure were found with 3 and 30 μg of BAY2586116 vs placebo in pigs. Similarly, BAY2586116 improved pharyngeal collapsibility by an average of approximately 2 cm H2O vs placebo, regardless of topical application method and dose (P < .008, mixed model) in participants with OSA. INTERPRETATION Acute topical application of BAY2586116 improves upper-airway collapsibility in anesthetized pigs and sleeping humans with OSA. These novel physiologic findings highlight the therapeutic potential to target POTASSIUM channel mechanisms to treat OSA. TRIAL REGISTRY ClinicalTrials.gov; No.: NCT04236440; URL: www. CLINICALTRIALS gov.
Collapse
Affiliation(s)
- Amal M Osman
- Adelaide Institute for Sleep Health and FHMRI Sleep Health, College of Medicine and Public Health, Flinders University, Adelaide.
| | - Sutapa Mukherjee
- Adelaide Institute for Sleep Health and FHMRI Sleep Health, College of Medicine and Public Health, Flinders University, Adelaide; Respiratory and Sleep Service, Southern Adelaide Local Health Network, SA Health, SA, Australia
| | - Thomas J Altree
- Adelaide Institute for Sleep Health and FHMRI Sleep Health, College of Medicine and Public Health, Flinders University, Adelaide; Respiratory and Sleep Service, Southern Adelaide Local Health Network, SA Health, SA, Australia
| | - Martina Delbeck
- Research & Development, Pharmaceuticals, Bayer AG, Wuppertal
| | | | - Michael Hahn
- Research & Development, Pharmaceuticals, Bayer AG, Wuppertal
| | - Tina Lang
- Research & Development, Pharmaceuticals, Bayer AG, Wuppertal
| | - Charles Xing
- Research & Development, Pharmaceuticals, Bayer AG, Wuppertal
| | - Thomas Muller
- Research & Development, Pharmaceuticals, Bayer AG, Wuppertal
| | - Gerrit Weimann
- Research & Development, Pharmaceuticals, Bayer AG, Wuppertal
| | - Danny J Eckert
- Adelaide Institute for Sleep Health and FHMRI Sleep Health, College of Medicine and Public Health, Flinders University, Adelaide
| |
Collapse
|
2
|
Carberry JC, Burke PGR, Osman AM, Jugé L, Toson B, Gandevia SC, Butler JE, Bilston LE, Eckert DJ. Regional genioglossus reflex responses to negative pressure pulses in people with obstructive sleep apnea. J Appl Physiol (1985) 2022; 133:755-765. [PMID: 35771222 DOI: 10.1152/japplphysiol.00083.2021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Tongue and upper airway dilator muscle movement patterns during quiet breathing vary in people with obstructive sleep apnea (OSA). Many patients have inadequate or counterproductive responses to inspiratory negative airway pressure that likely contributes to their OSA. This may be due, at least in part, to inadequate or non-homogeneous reflex drive to different regions of the largest upper airway dilator, genioglossus. To investigate potential regional heterogeneity of genioglossus reflex responses in OSA, brief suction pulses were applied via nasal breathing mask and electromyogram (EMG) was recorded in 4 regions (anterior oblique, anterior horizontal, posterior oblique, posterior horizontal) using intramuscular fine wire electrodes in 15 people with OSA. Genioglossus short-latency reflex excitation amplitude had regional heterogeneity (horizontal vs. oblique regions) when expressed in absolute units but homogeneity when normalized as a percentage of the immediate (100ms) pre-stimulus EMG. Regional variability in reflex morphology (excitation and inhibition) was present in one third of participants. Minimum cross-sectional area (CSA) of the pharyngeal airway quantified using MRI and may be related to the amplitude of the short-latency reflex response to negative pressure such that we found that people with a smaller CSA tended to have greater reflex amplitude (e.g. horizontal region r2=0.41, p=0.01). These findings highlight the complexity of genioglossus reflex control, the potential for regional heterogeneity and the functional importance of upper airway anatomy in mediating genioglossus reflex responses to rapid changes in negative pressure in OSA.
Collapse
Affiliation(s)
- Jayne C Carberry
- Adelaide Institute for Sleep Health, Flinders University, Adelaide, SA, Australia.,Neuroscience Research Australia, Sydney, New South Wales, Australia.,University College Dublin, School of Medicine, Ireland
| | - Peter George Redmayne Burke
- Neuroscience Research Australia, Sydney, New South Wales, Australia.,UNSW Sydney, Randwick, Australia.,Department of Biomedical Sciences, Macquarie University, Australia
| | - Amal M Osman
- Adelaide Institute for Sleep Health, Flinders University, Adelaide, SA, Australia.,Neuroscience Research Australia, Sydney, New South Wales, Australia.,UNSW Sydney, Randwick, Australia
| | - Lauriane Jugé
- Neuroscience Research Australia, Sydney, New South Wales, Australia.,UNSW Sydney, Randwick, Australia
| | - Barbara Toson
- Adelaide Institute for Sleep Health, Flinders University, Adelaide, SA, Australia
| | - Simon C Gandevia
- Neuroscience Research Australia, Sydney, New South Wales, Australia.,UNSW Sydney, Randwick, Australia
| | - Jane E Butler
- Neuroscience Research Australia, Sydney, New South Wales, Australia.,UNSW Sydney, Randwick, Australia
| | - Lynne E Bilston
- Neuroscience Research Australia, Sydney, New South Wales, Australia.,UNSW Sydney, Randwick, Australia
| | - Danny J Eckert
- Adelaide Institute for Sleep Health, Flinders University, Adelaide, SA, Australia.,Neuroscience Research Australia, Sydney, New South Wales, Australia.,UNSW Sydney, Randwick, Australia
| |
Collapse
|
3
|
Abstract
Multiple Sclerosis (MS) is a common neuroinflammatory disorder which is associated with disabling clinical consequences. The MS disease process may involve neural centers implicated in the control of breathing, leading to ventilatory disturbances during both wakefulness and sleep. In this chapter, a brief overview of MS disease mechanisms and clinical sequelae including sleep disorders is provided. The chapter then focuses on obstructive sleep apnea-hypopnea (OSAH) which is the most prevalent respiratory control abnormality encountered in ambulatory MS patients. The diagnosis, prevalence, and clinical consequences as well as data on effects of OSAH treatment in MS patients are discussed, including the impact on the disabling symptom of fatigue and other clinical sequelae. We also review pathophysiologic mechanisms contributing to OSAH in MS, and in turn mechanisms by which OSAH may impact on the MS disease process, resulting in a bidirectional relationship between these two conditions. We then discuss central sleep apnea, other respiratory control disturbances, and the pathogenesis and management of respiratory muscle weakness and chronic hypoventilation in MS. We also provide a brief overview of Neuromyelitis Optica Spectrum Disorders and review current data on respiratory control disturbances and sleep-disordered breathing in that condition.
Collapse
Affiliation(s)
- R John Kimoff
- Respiratory Division and Sleep Laboratory, McGill University Health Centre, McGill University, Montreal, QC, Canada; Respiratory Epidemiology and Clinical Research Unit, Research Institute of McGill University Health Centre, Montreal, QC, Canada.
| | - Marta Kaminska
- Respiratory Division and Sleep Laboratory, McGill University Health Centre, McGill University, Montreal, QC, Canada; Respiratory Epidemiology and Clinical Research Unit, Research Institute of McGill University Health Centre, Montreal, QC, Canada
| | - Daria Trojan
- Department of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University Health Centre, McGill University, Montreal, QC, Canada
| |
Collapse
|